999 E. Arques Ave
Sunnyvale, CA 94085-4521
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs. Currently we have three candidates in clinical development and several molecules in preclinical development. Ibrutinib (PCI-32765), first-in-human, oral therapy that is a selective, irreversible Bruton’s tyrosine kinase (BTK) inhibitor being investigated in B-cell hematologic malignancies. PCI-27483, a subcutaneously administered Factor VIIa inhibitor targeting tissue factor expressing tumors in oncology (being investigated in pancreatic cancer). Abexinostat hydrochloride (PCI-24781), an oral Histone Deacetylase (HDAC) inhibitor being investigated in oncology applications, such as lymphomas and solid tumor malignancies. BTK Inhibitor compounds for autoimmune diseases in preclinical development. Isoform selective HDAC8 inhibitors in preclinical development.
Clinical Development Stage
IND; Phase I; Phase II; Phase III; PreClinical